External sources (12 main papers + 4 contextual)

Gershon E., Issler O., Hadad A., Tov-Perry I., Reiss N., Chen A. (2025). "Mild chronic stress promotes female fertility via the ovarian CRF receptor." Cell Communication and Signaling, 23, 354. DOI: 10.1186/s12964-025-02371-0. PMID: 40813666. PMC12351781.
Prudente S., Bailetti D., Mendonca C., Mannino G. C., Fontana A., De Cosmo S., Andreozzi F., Doria A., Trischitta V. (2023). "Novel corticotropin-releasing hormone receptor genes (CRHR1 and CRHR2) linkage to and association with polycystic ovary syndrome." Journal of Ovarian Research, 16(1), 158. DOI: 10.1186/s13048-023-01159-5. PMID: 37543650. PMC10403835.
Park J. Y., Mun S. T., Jo M. (2023). "Cortisol/glucocorticoid receptor: a critical mediator of the ovulatory process and luteinization in human periovulatory follicles." Human Reproduction, 38(4), 671–685. DOI: 10.1093/humrep/dead017. PMID: 36752644. PMC10068287.
Park J. Y., Su J., Jo M. (2024). "Intrafollicular concentrations of biologically active cortisol in women rise abruptly shortly before ovulation and follicular rupture." Human Reproduction, 39(3), 578–589. DOI: 10.1093/humrep/dead269. PMID: 38199801.
Flaherty S. E. III, Bezy O., Paulhus B. L., Song L., Piper M., Pang J., Park Y. J., Asano S., Lien Y.-C., Bhatt N. D., Gupta R. K., et al. (2023). "Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity." Nature Communications, 14, 3953. DOI: 10.1038/s41467-023-39597-w. PMID: 37402735. PMC10319809.
Chen J., Tan B., Lin Q., Tang K., Wang Y., He P., Li M., Tan J., Liu D. (2024). "Activation of P2X7 Receptor Mediates the Abnormal Ovulation Induced by Chronic Restraint Stress and Chronic Cold Stress." Biology (Basel), 13(8), 620. DOI: 10.3390/biology13080620. PMC11351884.
Tan H., Cheng W., Yan X., Wu Y. (2024). "Psychological stressors involved in the pathogenesis of premature ovarian insufficiency and potential intervention measures." Gynecological Endocrinology, 40(1), 2360085. DOI: 10.1080/09513590.2024.2360085. PMID: 38824406.
Carbone S. E., Veschi S., Roca V., Quinteros F. A., Cremaschi G. A., Cabilla J. P. (2018, cited in 2023-2024). "Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis." PLOS One, 13(11), e0197698. DOI: 10.1371/journal.pone.0197698. PMID: 30412574. PMC6235236.
Vergetaki A., Jeschke U., Vrekoussis T., Taliouri E., Sabatini L., Papakonstanti E. A., Makrigiannakis A. (2013, continuity base 2024). "Differential Expression of CRH, UCN, CRHR1 and CRHR2 in Eutopic and Ectopic Endometrium of Women with Endometriosis." PLOS One, 8(4), e62313. DOI: 10.1371/journal.pone.0062313. PMID: 23638035. PMC3634725.
Wu Y., Li P., Zhang D., Sun Y. (2016, current mechanistic base 2024). "Local Regeneration of Cortisol by 11β-HSD1 Contributes to Insulin Resistance of the Granulosa Cells in PCOS." Journal of Clinical Endocrinology & Metabolism, 101(5), 2168–2177. DOI: 10.1210/jc.2016-1119. PMID: 26934392.
Mahbod Ebrahimi M., Khansari N., et al. (2023). "Roles of endoplasmic reticulum stress in the pathophysiology of polycystic ovary syndrome." Frontiers in Endocrinology, 14, 1124405. DOI: 10.3389/fendo.2023.1124405. PMC9975510.
Hampson L. E., Ellis E. L., Lin J., et al. (2023). "Glucocorticoids and Their Receptor Isoforms: Roles in Female Reproduction, Pregnancy, and Foetal Development." Cells, 12(16), 2079. DOI: 10.3390/cells12162079. PMID: 37626888. PMC10452123.

Inherited contextual sources L1-L2.1 used:

Du W. et al. 2023 (Front Endocrinol PMC10834786) — vagotomy reverses PCOS, already analyzed in L1.6.
Patel B. et al. 2024 (Ann NYAS PMID 39287750) — kisspeptin HPA↔HPO node, already in L2.1.
Asakura H., Zwain I. H., Yen S. S. (1997, anatomical base). "Expression of genes encoding corticotropin-releasing factor (CRF), type 1 CRF receptor, and CRF-binding protein and localization of the gene products in the human ovary." J Clin Endocrinol Metab, 82(8), 2720–2725. PMID: 9253360.
Muramatsu Y., Sugino N., Suzuki T., Totsune K., Takahashi K., Tashiro A., Hongo M., Oki Y., Sasano H. (2001-2007, primate corpus luteum, validated in 2024 review). "Expression of CRH-urocortin-receptor-binding protein system in primate ovary during the menstrual cycle." Endocrinology, 148(11), 5385–5396. DOI: 10.1210/en.2007-0145. PMID: 17690168.

Baseline knowledge (what I know before searching)

The classical doctrine of the HPA-HPO axis holds that CRH is strictly hypothalamic and that its effect on the ovary is indirect, via systemic cortisol (long endocrine axis) and via GnRH suppression (central neural axis — the latter established in L2.1). In this model, the ovary is a passive target organ: it receives LH/FSH and cortisol, and responds.

This doctrine has been obsolete since the late 1990s. The ovary is both a source and target of CRH: theca cells, the corpus luteum, the stroma, and the oocyte itself express the CRH gene and secrete bioactive CRH. The ovary also expresses both receptors (CRHR1 dominant in theca, CRHR2 dominant in granulosa/stroma) and the binding protein CRH-BP (CRHBP), which modulates local ligand availability. It co-localizes with urocortin 1 (UCN1), urocortin 2 (UCN2), and urocortin 3 (UCN3) — peptides from the same family with different affinities for CRHR1/CRHR2. In other words: the ovary has a complete paracrine-autocrine CRH micro-axis, anatomically and functionally analogous to the central HPA axis but operating intra-follicularly with its own kinetics (minutes-hours) and partially independent from systemic cortisol.

The functional meaning of this micro-axis was debated for two decades because the data were contradictory. In vitro studies in human granulosa-lutein cells showed that CRH inhibits steroidogenesis (drop in E2, P4, androgens). Studies in theca from pre-ovulatory follicles showed that CRH inhibits LH-stimulated DHEA and androstenedione. But in parallel, anatomical studies showed that CRH and CRHR1 expression increases markedly in mature pre-ovulatory follicles compared with small antral follicles — suggesting active physiological function, not pathology. The open question was: does the ovary manufacture CRH to slow steroidogenesis under stress (the "protective brake" model) or does it manufacture it as part of the normal pre-ovulatory inflammatory cascade (the "ovulation is a physiological inflammatory event, CRH is one of the triggers" model)?

The answer — which reorients the entire field — emerges between 2023 and 2025 through three convergences:

(1) Ovulation is an active inflammatory event, not the passive culmination of follicular growth. The LH surge triggers a cascade of inflammatory mediators (prostaglandins, cytokines, MMPs, local cortisol) that culminates in follicular rupture. Intrafollicular cortisol rises abruptly hours before ovulation (Park 2024). Ovarian CRH is a physiological part of this cascade — not a disruptor.

(2) MILD chronic stress does not suppress fertility — it facilitates it (Gershon 2025, paradigm-shifting finding). In mice, 4 weeks of mild chronic variable stress increase ovulation rate, litter size, and upregulate CRHR1 in interstitial theca. CRFR1 knockouts and treatment with an intra-ovarian CRH antagonist abolish the effect. This reverses the dogma of "stress = poor fertility" in its simplistic form and establishes an inverted U: mild acute/chronic-mild stress facilitates ovulation via ovarian CRHR1; severe chronic stress suppresses via the central axis (L2.1).

(3) CRHR1 and CRHR2 are PCOS susceptibility genes (Prudente 2023). Twenty-two variants of CRHR1 and one of CRHR2 linked to PCOS in Italian families. In silico, the risk variants promote inactive chromatin in the ovary. This implies that the ovarian-CRH system is not an epiphenomenon — it is a causal node of a common reproductive disorder.

The emerging model: the ovary is an endocrine-immune organ with its own local mini-HPA. Intrafollicular cortisol has two sources: systemic cortisol that arrives through blood (modulated by central HPA) and cortisol regenerated locally by the enzyme 11β-HSD1 in granulosa (Wu 2016, Park 2023, Park 2024). Ovarian CRH modulates local conversion, LH sensitivity, cumulus-oocyte maturation, and atresia. In normal physiology, this entire apparatus is adaptive (it ensures ovulation under everyday stress). In pathology (PCOS, endometriosis, POI), the same apparatus derails because the magnitude of the CRH stimulus or receptor sensitivity moves outside the physiological range.

This rewrites L2.1: the net effect of chronic stress on human fertility is not the simple sum of the central axis. It is the interaction between central suppression (KNDy/GnRH slowed by CRH-PVN, L2.1) and local modulation (ovarian CRHR1, inverted U according to severity/chronicity). A woman may have slowed LH pulses but the ovary partially "rescues" through local CRH — or she may have normal pulses and the ovary may derail because of dysregulated local CRH (stress-mediated PCOS).

L1 is also rewritten: the progesterobolome and microbial biliary cortisol (L1.2) reach the ovary as substrate — but now we know that the ovary itself produces CRH and regenerates cortisol locally. This means dysbiosis not only affects the circulating substrate, but also that a dysfunctional ovary may partially compensate through local CRH/cortisol (individual resistance) or amplify damage if the local system is also broken. The "microbial-vagal buffer" of H13 now requires co-considering a second parallel buffer: the intra-ovarian CRH-cortisol system.

Findings from recent papers (2023-2025)

Gershon et al. 2025 (Cell Commun Signal, PMC12351781) — the paradigmatic paper that reverses the dogma "stress is always bad." In ICR mice, 4 weeks of mild chronic variable stress (CVS) (9 stressors/week, ~2/day, light/dark mix) produce: (i) significantly elevated ovulation rate in the following cycle, (ii) increased litter size, (iii) low serum E2 (not high, counterintuitive), (iv) decreased ovarian 17β-HSD3 expression (enzyme that produces testosterone from androstenedione), (v) upregulation of CRHR1 in theca-interstitial cells of large follicles. The causal piece: in CRHR1 knockouts and in WT female mice with intra-ovarian injection of β-asstressin (peptidic CRH antagonist), the effect disappears — ovulation drops, E2 rises, 17β-HSD3 rises. In other words: mild chronic stress recruits the ovarian CRHR1 system to redirect steroidogenesis (less androgen/E2, greater ovulatory efficiency) — a reproductive adaptation to stress, not pathology. Radical implication: altered LH pulsatility (L2.1) and KNDy suppression are not the last word; the ovary has a parallel lever that can facilitate fertility under moderate stress. The clinical paradox of women who conceive during periods of acute-moderate stress (stressful vacations, moves, recently completed exams) has a mechanistic basis.

Prudente et al. 2023 (J Ovarian Res, PMC10403835) — first evidence of CRHR1/CRHR2 as PCOS susceptibility genes. 212 Italian families with T2D phenotyped for PCOS. Analysis of 36 CRHR1 + 18 CRHR2 variants under parametric inheritance models. Result: 22 CRHR1 variants and 1 CRHR2 variant significantly linked or in linkage disequilibrium with PCOS. In silico analysis predicts that the risk variants promote inactive chromatin specifically in the ovary — not in the hypothalamus, not in the pituitary. CRHR1 and CRHR2 are known for their role in insulin secretion (both receptors expressed in pancreatic islets), so the risk variants create a combined "mental-metabolic risk": they alter stress-reactive tone + insulin secretion + ovarian chromatin. Implication: PCOS is not "only" hypothalamic or "only" metabolic — it has a genetically determined intra-ovarian component that operates through CRHR. For population context, this partially explains why two women with the same perceived stress level and the same BMI develop symptomatic PCOS differently: polymorphisms in CRHR1/CRHR2 modulate the local ovarian response.

Park 2023 (Hum Reprod, PMC10068287) + Park 2024 (Hum Reprod) — intrafollicular cortisol rises ABRUPTLY hours before ovulation. Park 2023 characterizes peri-ovulatory follicles from women in natural cycles: hCG (which simulates the LH surge) induces coordinated upregulation of HSD11B1 (11β-HSD1, activates cortisone→cortisol), NR3C1 (glucocorticoid receptor), FKBP4/FKBP5 (sensitivity modulators). GR antagonists attenuate the hCG-induced increase in progesterone and cortisol in luteinized granulosa and reduce genes of the ovulatory cascade. Park 2024 measures biologically active intrafollicular cortisol (unbound) and shows an abrupt peak in the hours before follicular rupture — the local equivalent of the systemic stress response. Implication: ovulation REQUIRES a functional local cortisol-GR response. Intra-ovarian cortisol is not a marker of pathological stress — it is an obligatory physiological signal of the ovulatory process. This reconciles the classic P4-cortisol "antagonism" (future L2.3): cortisol and P4 do not always compete; in the peri-ovulatory follicle they co-act on GR as part of maturation.

Wu 2016 (JCEM, current mechanistic base) — elevated ovarian 11β-HSD1 in PCOS-IR. In granulosa from women with insulin-resistant PCOS, 11β-HSD1 (not 11β-HSD2) is significantly elevated → more cortisone→cortisol conversion locally → high follicular cortisol → attenuated Akt phosphorylation → granulosa insulin resistance → altered follicular maturation. Selective inhibitor BVT.2733 reverses PCOS symptoms in an animal model. Implication: PCOS has a local pathway of intra-ovarian hypercortisolism independent of systemic cortisol. A woman with normal morning cortisol may have chronically high intrafollicular cortisol if her granulosa expresses elevated 11β-HSD1. This explains the clinical disconnection between measurable systemic cortisol and observed ovarian dysfunction.

Flaherty 2023 (Nat Commun, PMC10319809) — dose and duration of CRHR2 agonism reverse the metabolic effect. UCN2 (which binds exclusively to CRHR2) at an acute dose induces systemic and skeletal muscle insulin resistance. Chronic UCN2 (adenovirally elevated for weeks) improves glucose tolerance and insulin sensitivity. Mechanism: CRHR2 recruits Gs at low concentration (cAMP+ → acute metabolic signal) and Gi/β-arrestin at high chronic concentration (internalization → desensitization). The receptor becomes "depleted" and the signal changes sign. Critical implication for L2.2: the same principle probably operates in the ovary. Acute CRHR1/CRHR2 activation → one phenotype; chronic activation → the opposite, through desensitization via internalization + β-arrestin. This resolves the Gershon 2025 paradox (mild chronic stress "helps" ovulation): the ovarian CRH system is reconfigured through adaptive desensitization, not through pure ligand exposure. If stress is severe or discontinuous in pulses, desensitization does not become established and the acute signal predominates (intermittent pro-ovulatory signal with luteal dysfunction → PCOS-like) or total suppression (FHA).

Chen 2024 (Biology, PMC11351884) — chronic restraint stress reduces ovulation through P2X7-NPPC, not through CRH alone. Chronic restraint (10 days) + chronic cold model in mice → drop in number of corpora lutea. P2X7 receptor (purinergic) elevated in ovary → upregulation of NPPC (natriuretic peptide C-type) in granulosa → altered cumulus maturation + ovarian fibrosis (IL-1β, TGF-β1, MMP2). Antagonist A-438079 partially rescues. Implication: severe chronic stress activates a second purinergic ovarian axis ADDITIONAL to ovarian CRH. Damage is not monocausal — multiple intra-ovarian systems (CRH-cortisol-purinergic-noradrenergic-microglial) add damage. Defines local ovarian allostatic load as an operational concept.

Tan 2024 (Gynecol Endocrinol, DOI 10.1080/09513590.2024.2360085) — bidirectional psychological-POI with ovarian CRH as bridge. Systematic review of psychological stressors (anxiety, depression, ACEs, workload) as an independent risk factor for POI. Proposed mechanisms: central HPA (cortisol → granulosa 11β-HSD1, already in Wu 2016) + SAM activation (ovarian norepinephrine, already in Stener-Victorin 2024 L2.1) + paracrine ovarian CRH activating apoptosis via IL-1/TNF-α in granulosa + hypothalamic microglia via LPS-dysbiosis (inherited L1.6) → accelerated atresia → POI. Implication: POI has an operationalizable stress-mediated component — and ovarian CRH is one of the nodes. For practical applications, young women with high ACEs + work stress + short cycles could benefit from specific intervention years before the classic diagnosis of POI by low AMH.

Carbone 2018 (PLOS One, PMC6235236) — antalarmin (CRHR1 antagonist) reduces endometriosis in a murine model. Confirms that CRHR1 actively maintains the endometriotic lesion through local inflammation. Vergetaki 2013 (PMC3634725) showed CRH/UCN/CRHR1/CRHR2 dramatically elevated in eutopic and ectopic endometrium of women with endometriosis vs healthy women. Implication: the three most common reproductive pathologies (PCOS, endometriosis, POI) share dysregulation of the local ovarian/endometrial CRH axis. This suggests a common therapeutic target.

Mahbod Ebrahimi 2023 (Front Endocrinol, PMC9975510) — ER stress + UPR in PCOS granulosa. Endoplasmic reticulum stress is activated in granulosa from PCOS patients and models, integrating hyperandrogenism + IR + inflammation + oxidative stress. CRH/UCN are known inducers of ER stress in other tissues. Implication: chronic ovarian CRH probably acts partly through granulosa ER stress — an underexplored mechanism that connects L2.2 with ovarian aging. Testable pathway.

Hampson 2023 (Cells, PMC10452123) — GR isoforms in reproduction. Updated review of NR3C1 isoforms (GRα/β/γ/A/B/C/D) in ovary, uterus, placenta. GRα is dominant in granulosa; GRβ (dominant negative antagonist) varies individually. NR3C1 polymorphisms (BclI, N363S, ER22/23EK) modulate sensitivity to intra-ovarian cortisol. Implication: the effect of intrafollicular cortisol varies 2-5× between women because of GR genetics. This is inherited directly from hypothalamic polymorphism (L2.1 already listed NR3C1 BclI G/G as hypersensitivity). A woman who is centrally hypersensitive is probably also ovarianly hypersensitive — the "cortisol-reactive biotype" manifests at multiple levels of the system.

Asakura 1997 / Muramatsu 2007 — baseline anatomy (current). Asakura: CRH gene + CRHR1 + CRHBP expressed in normal human ovary; CRH in theca and luteal cells; CRHR1 in stroma, theca, cumulus oophorus; granulosa lacks CRH/CRHR1 but responds functionally (paracrine from theca/stroma). Muramatsu: in primate corpus luteum, UCN/UCN2/CRHR1/CRHR2 all expressed with a peak in mid-luteal phase. CRHBP rises post-LH-withdrawal. These findings (≥15 years old) remain the baseline anatomical map on which Gershon 2025 builds the functional effect.

Du 2023 (Front Endocrinol, PMC10834786, already in L1.6) — vagotomy reverses PCOS in rats, lateral asymmetry. Left vagotomy lowers ovarian norepinephrine; right vagotomy does not. This implies that the vagus modulates the ovarian sympathetic-noradrenergic axis locally. Combined with ovarian CRH (current L2.2), a triple circuit emerges: afferent vagus ↔ ovarian CRH ↔ ovarian sympathetic NA → all converge in theca/granulosa, all modifiable through peripheral intervention (nutritional vagal + microbial-vagal buffer + sympathetic reduction).

Complete molecular mechanism — the dual central + ovarian HPA axis

                    CENTRAL HPA AXIS (L2.1)                    LOCAL OVARIAN HPA AXIS (L2.2 — new)
                    ───────────────────                       ─────────────────────────────

Stressor ─► Amygdala/PFC ─► PVN-CRH ──┐
                                       │
                ┌──► ACTH ─► Adrenal ─► systemic CORTISOL ──────────────────────────┐
                │                                                                     │
                │                                                                     ▼
                └──► Fast central ARC pathway                         [Follicular blood: cortisol arrives]
                     (Phumsatitpong 2023):                                            │
                     CRH-PVN ─► local ARC GABA ─► KNDy↓ ─► GnRH↓                       │
                                                          │                            │
                                                          ▼                            │
                                                  LH/FSH pulses ──► ovary              │
                                                                       │                │
                                                                       │                │
                                                                       ▼                ▼
                              ┌──────────────────────────────────────────────────────────────┐
                              │                  OVARY (ANTRAL/PREOVULATORY FOLLICLE)        │
                              │                                                                │
                              │      THECA: produces local CRH + UCN1                         │
                              │       ├──► autocrine on theca CRHR1 ─► modulates CYP17A1       │
                              │       │       ─► androgen production (LH-stimulated)           │
                              │       └──► paracrine on granulosa (without its own CRH)        │
                              │                                                                │
                              │      GRANULOSA: expresses CRHR1 + CRHR2 + 11β-HSD1 + GR (NR3C1)│
                              │       ├──► CRH/UCN ↑ ─► inhibits E2 + P4 via IL-1              │
                              │       ├──► 11β-HSD1 ↑ ─► cortisone→LOCAL cortisol ↑            │
                              │       │       ─► autocrine GR ─► (a) facilitates ovulation if   │
                              │       │           abrupt pre-ovulatory peak (Park 2024)         │
                              │       │       ─► (b) attenuates Akt/insulin if chronic (PCOS, Wu)│
                              │       └──► ER stress + UPR if chronic-intense (Ebrahimi 2023)  │
                              │                                                                │
                              │      STROMA/CORPUS LUTEUM: UCN1/2/3 + CRHR1/CRHR2 + CRHBP      │
                              │       ├──► CRHBP ↑ post-LH-withdrawal: buffers free ligand     │
                              │       └──► modulates luteolysis (Muramatsu 2007)               │
                              │                                                                │
                              │      Ovarian sympathetic NORADRENERGIC INPUT (β-AR theca):     │
                              │       └──► amplifies theca androgen (PCOS-like)                │
                              │      Afferent VAGAL INPUT (NTS ─► PVN ─► ovary):               │
                              │       └──► modulates local tone (L vs R asymmetry; L1.6 Du 2023)│
                              │      MICROBIAL INPUT (LPS, SCFA, microbial biliary P4; L1.2-1.6):│
                              │       └──► substrate + inflammatory tone + buffer              │
                              └────────────────────────────────────────────────────────────────┘
                                                  │
                                                  ▼
                              FUNCTIONAL OUTPUT OF THE OVARY (depends on DOSE and DURATION
                              of ovarian CRH activation — inverted-U pattern, Gershon 2025):

                              Chronic MILD-MODERATE stress (theca CRHR1 ↑, adaptive desensitization):
                                ► facilitated ovulation
                                ► slightly low serum E2 (adaptive 17β-HSD3 ↓)
                                ► preserved/increased fertility

                              Chronic SEVERE or INTERMITTENT-PULSATILE stress (without desensitization):
                                ► route A (low insulin, high exercise): central LH suppression +
                                  ovary does not compensate → FHA (L2.1)
                                ► route B (high insulin, high sympathetic tone, granulosa ER stress):
                                  dysregulated chronic ovarian CRH + 11β-HSD1 ↑ + follicular
                                  cortisol ↑ + theca androgen ↑ → stress-mediated PCOS
                                ► route C (oxidative stress + autoimmunity + high ACEs):
                                  progressive granulosa apoptosis → accelerated atresia → POI

                              Endometriosis (parallel route L2.2):
                                ► CRH/UCN/CRHR1/CRHR2 elevated in eutopia and ectopia →
                                  chronic inflammation + adhesion + pain + infertility

Five operational principles of the dual-axis model:

Asymmetry of intrafollicular cortisol sources. Cortisol acting in granulosa comes from TWO sources: (a) systemic (regulated by central HPA, circadian rhythm, acute stress), (b) regenerated locally by 11β-HSD1 from cortisone (regulated by LH/hCG, insulin, local androgens). A woman may have normal serum cortisol and high intrafollicular cortisol, or vice versa.
Physiological vs pathological function of ovarian CRH is a matter of DOSE, DURATION, INTERMITTENCE. Physiological pre-ovulatory pulse = beneficial. Mild chronic = adaptive (Gershon). Severe chronic or intermittent pulsatile without desensitization = pathological. This inverted U is not a failure of the model — it is the very nature of GPCR regulation (Flaherty 2023 demonstrates it for CRHR2).
Genetic susceptibility CRHR1/CRHR2 modulates the ovarian response to stress. Risk variants (Prudente 2023) determine whether a woman responds with adaptive compensation (Gershon-like) or with derailment (PCOS-like) to the same objective level of stress. Together with NR3C1 polymorphisms (GR sensitivity) and FKBP5 (HPA rewiring, L2.1), they build an "ovarian stress-reactivity profile" that can be approximated phenotypically without genotyping.
Convergence of inputs in granulosa/theca. Five signals converge on the follicle: LH/FSH (central), systemic cortisol (HPA), paracrine ovarian CRH (local), sympathetic NA (autonomic), afferent-modulatory vagal input (microbial-vagal inherited L1). The "final phenotype" of the follicle is the integration of all five. This explains the enormous inter-individual variability and why single markers (FSH, AMH, cortisol) have limited predictive power.
The ovary has memory. Chronic granulosa ER stress (Ebrahimi 2023), hypothalamic epigenetic rewiring (L2.1), follicular reserves programmed in childhood (L1.3) — all converge on the fact that the accumulated history of stress matters more than the current level.

Gap in the literature

Absence of direct human data on CRH/UCN follicular fluid in LATAM. Gershon 2025 is mouse. Park 2023/2024 are North American/Asian women in IVF cycles. There is no LATAM characterization of intrafollicular CRH/UCN/cortisol levels in relation to psychosocial stress or traditional Mesoamerican diet.
Lack of formal integration of ovarian CRH + gut microbiome. L1.2 (progesterobolome, biliary cortisol → P4) + L1.6 (afferent vagus + LPS) are disconnected from the ovarian-CRH literature. No one has formally proposed that the microbial-vagal-progesterobolomic state determines local ovarian sensitivity to stress via modulation of input to the PVN + P4 substrate + follicular LPS inflammatory tone.
No validated noninvasive marker of the ovarian CRH axis exists. PSS-14 measures perceived stress (mental). Salivary cortisol measures central HPA. There is no direct clinical proxy for the ovarian CRH axis. But there are indirect research signals: inter-cycle variability, shortened luteal phase, increasing hirsutism/acne under stress, and onset of cyclic pelvic pain.
No literature on nutritional/behavioral intervention specific to ovarian CRH. Pharmacological antagonists (antalarmin, β-asstressin) are in pre-clinical stages. Are there foods/behaviors that specifically modulate this axis? Only indirect inference via systemic cortisol, ER stress, ANS balance.
Absence of a formal inverted-U model in humans. Gershon 2025 is definitive in mice. Human epidemiological data sometimes suggest the inverted U (women under moderate stress conceive well; women in severe crisis do not), but it has not been formalized.

New hypothesis H14 — "Dual central-ovarian HPA axis with ovarian inverted U determines reproductive fate under chronic stress"

Statement:

Under chronic stress, a woman's reproductive fate is not determined only by the magnitude of central HPA activation (systemic cortisol, KNDy/GnRH suppression), but by the interaction among three dimensions:

(i) Magnitude and pattern of the CRH stimulus (continuous chronic-mild vs chronic-severe vs intermittent-pulsatile), (ii) Local ovarian sensitivity (CRHR1/CRHR2 genetics + basal sympathetic NA tone + granulosa 11β-HSD1 expression + granulosa ER integrity), (iii) Systemic buffer (microbial-vagal + progesterobolome + neurobolome — inherited L1).

When these three axes are favorably aligned, a woman can tolerate moderate chronic stress without reproductive deterioration — and even experience ovulatory facilitation (Gershon 2025). When all three are unfavorable, the same objective level of stress produces ovarian derailment toward one of three clinical poles: FHA (route A), stress-mediated PCOS (route B), or POI/POF (route C).

The hypothesis predicts: the reproductive response to stress follows a bidimensional inverted U — the first axis is stressor severity (with an optimum in the chronic-mild zone), the second axis is composite system resilience (microbial-vagal + ovarian-local). Women with high resilience have a wider U (they tolerate more); women with low resilience have a U collapsed on both sides (any stress perturbs).

Operationalizable falsifiable predictions:

(P1) Ovulatory inverted U. In a 6-month prospective cohort with daily stress measurement and independent ovulation confirmation, the probability of detectable ovulation will follow an inverted U vs chronic stress level (weekly PSS-4 average over the last 90 days). Peak in the moderate-stress zone; drop in low-stress and high-stress.

(P2) Modulation by systemic buffer. The width of the inverted U will be significantly greater in the upper buffer quartile vs the lower quartile.

(P3) Phenotypic polarization. Women under sustained high chronic stress will bifurcate in estimable proportions toward three fates: (a) FHA-like (long cycles, shortened luteal phase), (b) PCOS-like (long cycles with androgenic symptoms), (c) functional preservation (regular cycles, high resilience).

(P4) Endometriosis-like correlate. In women with self-reported cyclic pelvic pain ≥3 cycles, the average of stress indicators will be significantly higher than in controls without pain, confirming a dysregulated-CRH component beyond PCOS/FHA.

(P5) Age at onset of irregularity. Women with self-reported ACEs ≥4 + high work/care load will have onset of menstrual irregularity on average 4-6 years earlier than women with low load/ACEs, operationalizing the stress-mediated POI component (Tan 2024).

Confidence level: High in component (i) and (ii) — directly supported by Gershon 2025, Prudente 2023, Park 2023/2024, Wu 2016. Medium-high in component (iii) — integration with L1 is original. Medium in quantitative magnitude of the U — no definitive human benchmarks exist. Clearly refutable: any of P1-P5 failing at the expected magnitude proportionally weakens H14.

Connection with previous lines

L1 (gut microbiome) — reinforcement of the unified model. Now the "distributed metabolic-neural sub-organ" (L1.6) gains an additional piece: the ovary is also a functional part of this sub-organ, connected by (a) enterohepatic endocrine route (biliary cortisol → microbial P4 via progesterobolome → reaches the ovary as substrate), (b) vagal neural route (NTS → PVN → ovary), (c) inflammatory route (systemic LPS → follicular TLR4 → ovarian CRH demand), (d) immune route (T cells, microglia, follicular macrophages). A single dysbiosis affects multiple functional components.

L2.1 (central GnRH-cortisol) — the missing piece. L2.1 showed how central stress suppresses GnRH. L2.2 shows that the ovary has its own response — sometimes opposite. This explains the clinical dissociation between documented central suppression and preserved fertility in some women. H13 (microbial-vagal buffer) and H14 (dual axis) are COMPLEMENTARY, not redundant — H13 is upstream of the entire system; H14 is the internal logic of the local ovarian axis.

L1.6 (vagus) — confirmed triple circuit. Du 2023 (vagotomy reverses PCOS) is now understood as release of afferent vagal input → reduction of paracrine ovarian CRH input + restoration of sympathetic NA ↔ parasympathetic ACh balance in theca. The vagus does not act directly on the ovary — it modulates the integration of central and local inputs to the ovary.

Anticipation L2.3 (P4 vs cortisol in GR) — the board is set. L2.3 will address P4-cortisol "competition" at GR. L2.2 already shows that this competition is not always antagonistic — pre-ovulatory intrafollicular cortisol (Park 2024) IS the physiological signal that triggers the peri-ovulatory cascade, and P4 + cortisol in luteinized granulosa co-signal GR. The classic "competition" is probably valid only in the mid-late luteal phase when dominant systemic P4 attempts to sustain the endometrium and cortisol elevated by chronic stress displaces it.

L9 (ovarian aging) — preview. Chronic granulosa ER stress (Ebrahimi 2023) + accelerated atresia from stress (Tan 2024 POI) + chronically elevated 11β-HSD1 (Wu 2016) → all converge in acceleration of functional ovarian aging. The local ovarian allostatic load proposed by H14 is mechanically equivalent to "biological age of the ovary" — older at the same chronological age when the three axes are miscalibrated.

Individual variability: who is more vulnerable to the dysregulated ovarian CRH axis

Genetics:

CRHR1 PCOS risk polymorphisms (22 variants, Prudente 2023)
CRHR2 risk variant (Prudente 2023)
NR3C1 (GR) — BclI G/G hypersensitive, N363S hypersensitive to cortisol, ER22/23EK hyposensitive.
HSD11B1 promoter polymorphisms — modulate granulosa 11β-HSD1 inducibility.
FKBP5 rs1360780 T/T — GR rewiring + delayed cortisol recovery.

Environmental/historical:

ACEs ≥4 — robust predictor of PCOS, endometriosis, and POI.
Multiple adult antibiotics — dysbiome.
Lactation/childbirth — longitudinal ovarian microbiome programming.
Primary caregiving load — chronic-passive stress.
Night shifts — circadian desynchronization.
High-intensity exercise >5h/week at low BMI — FHA predictor.
Ultra-processed diet >30% energy — PCOS-like predictor.

Observable co-markers:

Women with progressively short cycles + low AMH-proxy + ACEs ≥4 → risk of stress-mediated POI.
Women with long cycles + acne/hirsutism + high simple carbohydrate + sleep <6h → risk of stress-mediated PCOS.
Women with cyclic pain + heavy bleeding + post-prandial bloating → risk of CRH-mediated endometriosis.
Women with regular 28d cycles + mild symptoms + good diet + high buffer → resilient phenotype.

Practical formulation — Interventions on the ovarian CRH axis

Component 1 — Reduce regenerated intrafollicular cortisol (11β-HSD1 ↓): Dietary insulin sensitization reduces substrate for 11β-HSD1 activation. Strategy: (i) reduce morning glycemic load (no isolated sugar/carbs at breakfast), (ii) prioritize protein + fat + fiber at daybreak (stabilizes insulin and morning cortisol), (iii) inositol (myo + D-chiro 40:1, 2g+50mg/day — naturally present in black beans/lentils/citrus). Indirect evidence: insulin sensitizers reduce granulosa 11β-HSD1 expression (Wu 2016); nutritional inositol is the behavioral analog).

Component 2 — Modulate ovarian CRH through accessible systemic pathways: There is no known food that acts directly on ovarian CRH, but the cholinergic efferent vagal pathway suppresses local inflammation systemically (via α7-nAChR). Vagal stimulation: slow breathing 4-6 cpm + singing/humming + daily cold facial water + moderate aerobic exercise (not excessive). Combined with dietary SCFA-producers: circulating propionate reduces microglia + follicular inflammation. Mechanism: lower systemic LPS → lower ovarian TLR4 → lower inflammatory cascade → lower paracrine ovarian CRH demand.

Component 3 — Support ovarian GR with magnesium + B6: Pre-ovulatory intrafollicular cortisol (physiological, Park 2024) requires functional GR. NR3C1 polymorphisms modulate sensitivity. Magnesium (300-400 mg/d via beans, pumpkin seed, spinach, 70% cacao) stabilizes GR signaling + nNOS + GABA-A. B6 (P5P, 25-50 mg/d natural via banana, chickpea, tuna) cofactor for P4 + 5-HT synthesis. These do not "lower cortisol" — they calibrate the response.

Component 4 — Reduce ovarian noradrenergic tone: Sympathetic NA in theca elevates androgen (PCOS-like). Reduce: caffeine <200 mg/d (especially luteal phase), alcohol ≤3 drinks/week, restricted nighttime screen exposure (evening cortisol + NA), L-theanine (200 mg/d green matcha tea) reduces NA response to stress without sedation, glycine (3 g before sleep, improves nocturnal HRV).

Component 5 — Complete microbial buffer (inherited L1, reinforced): Probiotics + inulin 8-10 g/d + traditional fermented foods + chia + flaxseed + raspberry/pomegranate (urolithin A precursor). New addition in L2.2: foods rich in glycinates and betaine (quinoa, beet, cacao) — reported to upregulate GR sensitivity without raising cortisol.

Component 6 — Protect granulosa from ER stress: Vitamin C (kiwi, strawberry, chili, citrus — 200-500 mg/d bioavailable through food), natural N-acetyl cysteine via garlic/onion/cilantro, quercetin (red onion, apple with peel, caper) — reduce oxidative stress + granulosa ER stress.

Component 7 — Sleep + chronobiology: 7-9h, sleep before 23h, morning sunlight 10-15 min, blue-light restriction after 21h.

Component 8 — Recognition of the inverted U: Zero stress is not optimal. Moderate/challenging stress (exercise, projects, novelty) is desirable; chronic-passive stress (caregiving without rest, unresolved workplace conflict) is the harmful one.

Executive summary

The ovary is not a passive stress organ — it is a source and target of its own paracrine-autocrine CRH system, and under moderate chronic stress this system facilitates ovulation (Gershon 2025) — reversing the simplistic dogma that "stress is always bad for fertility." Under severe chronic or intermittent-pulsatile stress, however, the same system derails toward one of three clinical poles (FHA, stress-mediated PCOS, POI/endometriosis), with direction determined by the interaction among three axes: magnitude/pattern of the stressor, genetic ovarian sensitivity (CRHR1/CRHR2/NR3C1/HSD11B1), and the microbial-vagal-progesterobolomic systemic buffer (L1). H14 formalizes this logic as a bidimensional inverted U with the L1 buffer as a width modulator, testable in an existing cohort through stress and buffer stratification, and the intervention formulation (extension of components with dietary inositol, magnesium, B6, L-theanine, glycine, vitamin C and quercetin + educational recognition of the inverted U) offers a differentiable food and behavioral intervention with a deep mechanistic basis.